Editorial: adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease

Aliment Pharmacol Ther. 2017 Jan;45(1):178-179. doi: 10.1111/apt.13842.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Adalimumab*
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Crohn Disease
  • Humans
  • Immunologic Factors
  • Infliximab*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors
  • Infliximab
  • Adalimumab